Related Experiment Video

Updated: Jan 3, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K

Resolved HBV behavior during the treatment of chronic HCV infection with direct-acting antivirals

Salem Y Mohamed1, Baasim A Gaballah2, Hany Mohamed Elsadek1

  • 1Gastroenterology and Hepatology Unit, Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.

Gastroenterology and Hepatology From Bed to Bench
|November 22, 2019
PubMed

Insights

Treatment with direct-acting antiviral drugs (DAAs) for hepatitis C virus (HCV) showed a low risk of resolved hepatitis B virus (HBV) reactivation. This study followed patients with chronic hepatitis C, some with resolved HBV, during and after DAA therapy.

Area of Science:

  • Hepatology
  • Virology
  • Internal Medicine

Background:

  • Hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infection is increasingly recognized.
  • Previous studies on interferon therapy suggested a correlation between resolved HBV and lower treatment response, worse liver histology, and hepatocellular carcinoma development.

Purpose of the Study:

  • To assess and follow the course of resolved HBV during and after direct-acting antiviral drugs (DAAs) treatment.
  • To evaluate the risk of HBV reactivation in patients with chronic hepatitis C treated with DAAs.

Main Methods:

  • An observational, prospective study included 313 patients with chronic hepatitis C (CHC), 60 of whom had resolved HBV infection.
  • Patients received DAAs therapy for CHC and were monitored for viral markers (HCV RNA, HBV DNA) and liver enzymes (ALT, AST).
  • Follow-up occurred at baseline, week 4, end of treatment, and 12 weeks post-treatment.

Main Results:

  • Significant decreases in ALT and AST levels were observed in both groups, with stabilization during follow-up.
  • Treatment efficacy was comparable between patients with and without resolved HBV.
  • No cases of ALT flare were observed, indicating a low risk of HBV reactivation.

Conclusions:

  • The risk of resolved HBV reactivation during or after DAAs treatment for CHC is low.
  • DAAs therapy for CHC is safe in patients with resolved HBV infection.
Abstract

Keywords:
Direct-acting antiviralsHBV flareHCV infectionResolved HBV

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.3K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.1K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
662
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
149
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
182